Heart Failure
Patients with rheumatoid arthritis at higher risk for ‘avoidable’ hospitalization
WASHINGTON — Patients with rheumatoid arthritis demonstrate an elevated risk for avoidable hospitalizations, particularly for cardiovascular complications, compared with healthy controls, according to data presented at ACR Convergence 2024.
Breast calcification on mammogram ‘especially predictive’ of CVD risk in younger women
Breast arterial calcification seen on routine mammograms, especially among younger women, is associated with increased risk for death and adverse cardiovascular outcomes, including heart failure, myocardial infarction and stroke, data show.
Potassium binder helps optimize spironolactone use in patients with HF, hyperkalemia risk
CHICAGO — A potassium binder helped patients with HF who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk, researchers reported.
Heart failure drug may be ‘cardioprotective strategy’ for high-risk patients with cancer
CHICAGO — Treatment with the heart failure medication sacubitril/valsartan was associated with a lower risk for chemotherapy-related heart damage among high-risk patients with cancer, according to preliminary results of the SARAH trial.
Nasal spray form of bumetanide may be just as good as oral, IV
CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported.
In PCI for MI, spironolactone does not meet primary endpoints but may show benefit in HF
CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.
IV GLP-1 does not reduce death, stroke, organ damage after heart surgery
CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.
Catheter ablation superior to antiarrhythmic drugs in VT with ischemic cardiomyopathy
CHICAGO — Catheter ablation improved outcomes compared with antiarrhythmic drug therapy in patients with ventricular tachycardia and ischemic cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions.
Tirzepatide shows ‘practice-changing’ CV benefits for obesity-related heart failure
CHICAGO — In adults with HF with preserved ejection fraction and obesity, treatment with tirzepatide cut risk for CV death or worsening HF by 38% compared with placebo, with a parallel improvement in health status and exercise tolerance.
Transcatheter tricuspid valve replacement effective treatment for severe regurgitation
In patients with severe tricuspid regurgitation, transcatheter tricuspid valve replacement plus medical therapy improved outcomes compared with medical therapy alone, researchers reported at TCT 2024.